Tags: market
- Next Aurobindo Pharma | USFDA Approval – Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray. – This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company
- Previous Securities in Ban For Trade Date 19-MAR-2024: 1 ABFRL 2 BALRAMCHIN 3 BHEL 4 BIOCON 5 HINDCOPPER 6 MANAPPURAM 7 NATIONALUM 8 PEL 9 RBLBANK 10 SAIL 11 TATACHEM 12 ZEEL
Comments are closed.